Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient

This publication has 28 references indexed in Scilit:

• Mortalization of human promyelocytic leukemia HL-60 cells to be more susceptible to sodium butyrate-induced apoptosis and inhibition of telomerase activity by down-regulation of nucleophosmin/B23
  Oncogene, 1998
• Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1997
• Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1997
• Selective Induction of Apoptosis in Myeloid Leukemic Cell Lines by Monoacetone Glucose-3 Butyrate
  Biochemical and Biophysical Research Communications, 1994
• Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL‐60 leukemic cell line
  International Journal of Cancer, 1994
• Rapid alteration of c‐myc and c‐jun expression in leukemic cells induced to differentiate by a butyric acid prodrug
  FEBS Letters, 1993
• Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
  Cell, 1993
• Derivatives of butyric acid as potential anti‐neoplastic agents
  International Journal of Cancer, 1991
• Clinical pharmacology of sodium butyrate in patients with acute leukemia
  European Journal of Cancer and Clinical Oncology, 1987
• Butyric acid: A small fatty acid with diverse biological functions
  Life Sciences, 1980